Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Ascendis Pharma A/S Ordinary Share · Now $224.11
-5.8% in 7d after detection
Post-detection moves
1h
—
1d
+1.4%
3d
+3.8%
7d
-5.8%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS